Read time: 6 minutes
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
When paired with electron-activated dissociation (EAD) and automated data analysis, middle-down workflows provide a practical and reproducible way to gain meaningful structural insight into monoclonal antibodies and other complex protein therapeutics, all without the complexity of sample preparation needed for peptide-level characterization.
The limitations of CID‑based fragmentation in middle‑down workflows
Collision‑induced dissociation (CID) has long been used for fragmentation in protein and peptide analysis. However, when applied to middle‑down workflows, CID alone can introduce challenges that limit confidence in sequence confirmation and PTM localization:
- Extensive method development may be required; workflows often involve multiple fragmentation techniques and multiple injections with different parameters to achieve optimal sequence coverage
- Collisional activation leads to preferential cleavages of labile PTMs, leading to the loss of site-specific information about these modifications
- Fragmentation patterns generated by CID may lack the structural information needed for unambiguous sequence confirmation, particularly in complex or multi-specific modalities
As therapeutic formats evolve and timelines condense, these limitations highlight the need for newer analytical strategies that can be applied routinely, while also providing detailed structural information reproducibly and on pace with early drug development timelines.
The EAD advantage for middle‑down sequence analysis
EAD provides a complementary fragmentation mechanism that addresses the limitations of CID in middle‑down workflows. Benefiting from radical‑driven fragmentation mechanism, EAD produces extensive fragmentation of the peptide backbone, leading to high sequence coverage, while preserving labile PTMs like glycosylation.
When integrated into middle‑down analyses, EAD enables:
- High sequence coverage in a single injection, reducing the need for repeated analyses or complex method development
- Confident differentiation of candidate sequences, even when intact or subunit masses are identical
- Improved localization of labile PTMs, such as glycosylation, that may be difficult to characterize using vibrational fragmentation alone
These advantages make EAD particularly well-suited for more confident sequence confirmation and PTM analysis in modern biopharmaceutical workflows.
Why EAD delivers more informative fragmentation
EAD is a tunable, electron-based MS/MS fragmentation technology that uses radical-driven backbone cleavage rather than vibrational activation. By introducing low energy electrons, EAD generates complementary c and z-type fragment ions while preserving labile structural features that are often lost with CID.
Key technical advantages for middle-down workflows include:
- Radical-driven fragmentation, enabling high sequence coverage across large, multiply charged protein fragments
- Tunable electron kinetic energy, allowing efficient fragmentation across a wide mass and charge state range without extensive method optimization
- Preservation of labile PTMs and disulfide linked structures, supporting confident localization and structural confirmation
- Fast, high efficiency fragmentation compatible with UHPLC timescales, further enhanced by Zeno trap boosted MS/MS sensitivity
Together, these features provide the information-rich data required to confidently characterize complex biotherapeutic subunits beyond the practical limits of CID-only fragmentation.
Real‑world performance: Examples from middle‑down and subunit studies
Streamlined middle‑down analysis on the ZenoTOF systems
Single‑injection EAD‑based middle‑down workflows on the ZenoTOF 8600 system have demonstrated 75–85% sequence coverage of antibody subunits, with reproducible performance across replicate injections. This level of coverage enables routine sequence confirmation and PTM analysis without the need for multiple injections, multiple fragmentation strategies, or extensive optimization.
Confident analysis of complex modalities
For advanced formats such as tri-specific antibodies, EAD‑enabled middle‑down workflows provide the fragmentation detail needed to resolve ambiguity. In cases where two potential sequences share the same mass, EAD fragment ions can be used to confirm the correct sequence, supporting confident characterization of complex constructs in a single injection.
– Streamlined, single-injection workflows suitable for routine use
Sequence confirmation for the HC1 P1 subunit (13.5 kDa). Intact mass measurement revealed 2 possible sequences with identical masses for the HC1 P1 subunit. The detection of c-series ions, such as c7 and c8, in the high-quality EAD spectrum (A) confirmed the N-terminal sequence of the HC1 P1 subunit as “GGGSX” instead of “SGGGGSX” (B). The amino acid residues “X” and “Y” are not specified for proprietary reasons. The peaks labeled with “*” in panel A are the remaining precursors or charged reduced species.
Enhanced sensitivity with the ZenoTOF 8600 system
The ZenoTOF 8600 system further expands middle‑down and subunit capabilities by delivering enhanced MS sensitivity. This improvement supports:
- Detection of low‑abundant proteoforms
- Higher subunit sequence coverage at reduced sample load
- Confident characterization of PTM‑bearing variants, supported by EAD’s ability to preserve labile modifications
Enhanced subunit and middle-down analyses of biotherapeutics usingis the ZenoTOF 8600 system. The ZenoTOF 8600 system (left panel) is equipped with enhanced hardware components that provide >3X MS sensitivity increase for superior biotherapeutic analysis compared to the ZenoTOF 7600 system.4,5 This improvement enabled sensitive detection of biotherapeutic subunits and their proteoforms with a low sample load of 50 ng NISTmAb (middle panel). In addition, the sensitivity gain led to a higher sequence coverage (75%-85%) of NISTmAb (NIST) and trastuzumab (TRAS) subunits using the EAD-based middle-down MS compared to a coverage of 60%-68% obtained for these subunits using the previous platform (right panel)
Streamlined data analysis for middle-down workflows with Biologics Explorer software
A key enabler to make middle-down and subunit analysis routine is automated data analysis. Biologics Explorer software provides optimized workflow templates specifically designed for biotherapeutic protein sequencing and characterization. By combining EAD-based middle-down acquisition with workflow-driven data analysis, Biologics Explorer software enables consistent, single-injection characterization of biotherapeutic subunits, making middle-down analysis more accessible for routine use rather than a specialized, expert-only technique.
Within a typical workflow, EAD fragments are automatically identified, mapped, and annotated against the expected protein sequence. Results are presented in a single, integrated review environment, including sequence coverage maps, fragment ion summaries, and MS/MS spectral views, allowing users to quickly assess sequence confirmation and modification sites. This streamlined approach helps reduce the time and effort traditionally associated with middle-down data interpretation, supporting reproducible and confident decision making across discovery and development.
Where do middle‑down workflows fit in drug development?
In early biopharmaceutical development, analytical priorities often center on rapid structural confirmation, risk identification, and decision-making, rather than exhaustive characterization. Middle-down workflows are well-suited to this phase because they provide higher-level structural insight with fewer sample preparation steps than peptide-level methods, while delivering more detailed information than intact mass analysis alone.
By analyzing large proteolytic fragments or defined subunits, middle-down MS enables early confirmation of sequence integrity, disulfide connectivity, and key post-translational modifications, helping teams quickly identify structural liabilities or unexpected variants. This balance of information content, speed, and practicality allows scientists to assess molecular quality earlier in the pipeline, reduce analytical complexity, and focus development efforts on the most promising candidates before committing to more resource-intensive characterization strategies.
By combining accurate mass measurement, information‑rich fragmentation, and automated data analysis, EAD‑enabled middle‑down and subunit workflows on the ZenoTOF 7600 system, ZenoTOF 7600 + system and ZenoTOF 8600 system support higher confidence in core use cases:
- Primary sequence confirmation during development
- Differentiation of candidate sequences with identical mass
- Characterization of low‑abundance variants and proteoforms
- Localization of critical PTMs associated with sequence changes
Learn more about how EAD can enhance LC-MS workflows in biopharma, providing reliable data to inform critical decision points throughout the development pipeline.
Read the technical notes:
2. Enhanced biotherapeutic characterization with subunit and middle-down mass spectrometry workflows
Watch the webinar:
0 Comments